Xeris Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Xeris Pharmaceuticals's estimated annual revenue is currently $35.3M per year.
- Xeris Pharmaceuticals received $10.0M in venture funding in March 2018.
- Xeris Pharmaceuticals's estimated revenue per employee is $111,451
- Xeris Pharmaceuticals's total funding is $289.7M.
- Xeris Pharmaceuticals's current valuation is $275M. (January 2022)
- Xeris Pharmaceuticals has 317 Employees.
- Xeris Pharmaceuticals grew their employee count by 20% last year.
Xeris Pharmaceuticals Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Xeris Pharmaceuticals?
Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. The company's proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using syringes, auto-injectors, multi-dose pens, and infusion pumps. Xeris platforms have the potential to offer distinct advantages over existing formulations of marketed and development-stage products. In particular, XeriSol and XeriJect offer the opportunity to eliminate reconstitution, enable long-term room temperature stability, significantly reduce injection volume, and eliminate the requirement for intravenous (IV) infusion. These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare systemkeywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Solar Power
Number of Employees
Employee Growth %
Xeris Pharmaceuticals News
XERIS PHARMACEUTICALS, INC. TO ACQUIRE STRONGBRIDGE BIOPHARMA PLC IN STOCK AND CVR TRANSACTION, CREATING AN INNOVATIVE LEADER IN ENDOCRINOLOGY AND RARE DISEASES Transaction Creates Fast-Growing Biopharmaceutical Company with Two Commercial Assets and Robust Clinical Pipeline with Multiple Near- ...
Xeris Pharma's Gvoke is a stable and ready to use glucagon self-injector therapy. It has shown non-inferiority to Lilly and Novo Nordisk ...
After a three-month PDUFA extension, Xeris Pharmaceuticals and XERS investors are preparing for Gvoke's new PDUFA date on September ...
So shareholders might well want to know whether insiders have been buying or selling shares in Xeris Pharmaceuticals, Inc. (NASDAQ:XERS).
Xeris Pharmaceuticals, founded in 2005 in Austin, filed on Thursday with the Securities and Exchange Commission to go public on the Nasdaq Stock Exchange with an initial public offering valued at $75 million. The company, now based in Chicago, has strong ties to the Austin startup community. X ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Xeris Pharmaceuticals Funding
|2011-12-13||$1.5M||A||Central Texas Angel Network||Article|
|2018-03-09||$45.0M||Undisclosed||Silicon Valley Bank||Article|